Heat-inactivated vaccinia virus as a vaccine immune adjuvant

A vaccinia virus, heat inactivation technology, applied in the field of virology, immunotherapy, oncology, can solve the problem that the immune system is not activated

Pending Publication Date: 2020-08-18
MEMORIAL SLOAN KETTERING CANCER CENT
View PDF7 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite the presentation of antigens by cancer cells and the presence of immune cells that could potentially respond to tumor cells, in many cases the immune system is not activated or definitely suppressed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Heat-inactivated vaccinia virus as a vaccine immune adjuvant
  • Heat-inactivated vaccinia virus as a vaccine immune adjuvant
  • Heat-inactivated vaccinia virus as a vaccine immune adjuvant

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0147] Example 1: In immunized mice, co-administration of thermal iMVA with the model antigen chicken ovalbumin (OVA) enhanced OVA-specific CD8 in spleen and draining lymph nodes (dLN) + and CD4 + T cells and serum anti-OVA IgG antibody production.

[0148] This example demonstrates that thermal iMVA can act as a vaccine adjuvant to enhance antigen presentation by dendritic cells (DC). Mice were treated with or without heat iMVA (1x 10 7 pfu) together with OVA (10 μg) for two intramuscular (IM) immunizations with an interval of 2 weeks. One week after the second vaccination, mice were euthanized, and spleens, draining lymph nodes (dLNs) and blood were subsequently collected for OVA-specific T cell and antibody assessment ( Figure 1A ). To determine anti-OVA CD8 + T cell response, combining splenocytes (500,000 cells) with MHC class I as OVA (K b ) restricted peptide epitope of OVA 257-264 (SIINFEKL) peptide (SEQ ID NO: 1) was incubated for 12 h, after which it was ...

Embodiment 2

[0150] Example 2: In the production of antigen-specific CD8 + and CD4 + In terms of T cell response, thermal iMVA is superior to complete Freund's adjuvant (CFA).

[0151] Complete Freund's Adjuvant (CFA) contains heat-inactivated Mycobacterium tuberculosis in non-metabolizable oils (paraffin oil and mannidemonooleate). It also contains ligands for TLR2, TLR4 and TLR9. The antigen was co-injected with CFA to induce a Th1 dominant immune response. Currently, the use of CFA in humans is not permitted due to its toxicity profile, and its use in animals is limited to subcutaneous or intraperitoneal routes due to painful responses at the injection site and risk of tissue damage. To test whether thermal iMVA is superior to CFA, mice were vaccinated subcutaneously twice with OVA antigen + thermal iMVA or OVA + CFA 2 weeks apart, and the harvested spleen, dLN and blood were subsequently harvested as described in Example 1 , for anti-OVA CD8 + and CD4 + T cell and antibody r...

Embodiment 3

[0152] Example 3: Batf3-dependent effect of thermal iMVA-mediated vaccine adjuvants on antigen-specific T cell responses sex DC.

[0153] Batf3 is for CD103 + / CD8α + Transcription factor important for the development of lineage DCs that play an important role in the cross-presentation of viral and tumor antigens. Batf3-deficient mice fail to reject highly immunogenic tumors. To test whether STING or Batf3 plays a role in thermal iMVA-mediated vaccine adjuvant effects, WT C57B / 6, STING Gt / Gt or Batf3 - / - Mice were vaccinated twice subcutaneously with OVA+thermal iMVA two weeks apart. Then one week after the last vaccination, spleen, dLN and blood were harvested for analysis of cellular and humoral immune responses ( Figure 3A ). found that CD8 induced by thermal iMVA in the spleen + Anti-OVA IFN-γ in T cells + The percentage of T cells decreased from 1.2% in immunized WT mice to immunized Batf3 - / - 0.38% of mice (P- / - ; Figure 3B ). Additionally, CD8 induced b...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The technology of the present disclosure relates to the use of Heat-inactivated modified vaccinia Ankara (MVA) virus (Heat-iMVA) or Heat-inactivated vaccinia virus as a vaccine immune adjuvant. In particular, the present technology relates to the use of Heat-iMVA as a vaccine adjuvant for tumor antigens in cancer vaccines alone or in combination with immune checkpoint blockade (ICB) antibodies foruse as a cancer immunotherapeutic.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62 / 582,263, filed November 6, 2017, which is hereby incorporated by reference in its entirety. technical field [0003] The technology of this disclosure relates generally to the fields of oncology, virology and immunotherapy. The present technology relates to the use of heat-inactivated vaccinia virus as an adjuvant for vaccine immunization. Specifically, the present technology relates to heat-inactivated modified vaccinia Ankara (MVA) virus or "thermal iMVA" alone or in combination with immune checkpoint blocking (ICB) antibodies for use as cancer immunotherapeutics as tumor antigens in cancer vaccines The use of vaccine adjuvants. Background technique [0004] The following descriptions are provided to aid the reader's understanding. None of the information presented or references cited is admitted to be prior art in th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61K39/00A61K45/06A61K39/395A61P35/00A61P37/04
CPCA61K39/275A61K39/39A61K45/06A61K2039/5152A61K2039/5252A61K2039/54A61K2039/55588C12N2710/24132A61P37/04A61P1/04C12N7/00C12N2710/24131C07K16/2827A61K39/12Y02A50/30A61P35/00A61K39/001111A61K39/3955A61K2039/545C12N2710/24133
Inventor L·邓N·杨S·舒曼T·梅古布J·D·沃尔乔克
Owner MEMORIAL SLOAN KETTERING CANCER CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap